Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.53 |
| ▸ | DUSP3 | P51452 | 1/20 | 0.53 |
| ▸ | MEN1 | O00255 | 1/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.53 |
| ▸ | LMNA | P02545 | 1/20 | 0.53 |
| ▸ | DGKA | P23743 | 1/20 | 0.45 |
| ▸ | PRKCA | P17252 | 4/20 | 0.44 |
| ▸ | FAAH | O00519 | 2/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15319570 | 1.00 | KDM4E (0.53) | KDM4EDUSP3MEN1KMT2ALMNA | |
| 3-Hydroxybutyric Acid, (+/-)- SCHEMBL22300929 | 0.93 | KDM4E (0.47) | KDM4EDUSP3MEN1KMT2ALMNA | |
| 3-Hydroxybutyric Acid, (+/-)- SCHEMBL19976113 | 0.93 | KDM4E (0.47) | KDM4EDUSP3MEN1KMT2ALMNA | |
| SCHEMBL25476040 | 0.93 | KDM4E (0.47) | KDM4EDUSP3MEN1KMT2ALMNA | |
| SCHEMBL21471879 | 0.89 | PRKCA (0.45) | KDM4EDUSP3MEN1KMT2ALMNA | |
| SCHEMBL21471824 | 0.89 | PRKCA (0.45) | KDM4EDUSP3MEN1KMT2ALMNA | |
| SCHEMBL4805747 | 0.88 | KDM4E (0.53) | KDM4EDUSP3MEN1KMT2ALMNA | |
| SCHEMBL10415158 | 0.85 | LMNA (0.53) | KDM4EDUSP3MEN1KMT2ALMNA | |
| SCHEMBL21775801 | 0.83 | MAPT (0.43) | KDM4EDUSP3MEN1KMT2ALMNA | |
| SCHEMBL21775800 | 0.83 | MAPT (0.43) | KDM4EDUSP3MEN1KMT2ALMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 104 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3937656-B1 | TASTE-MASKING FORMULATION FOR KETONE BODY COMPOUNDS | NEUROENERGY VENTURES INC (US) | 2025-04-02 | — | — | EP | claimed |
| US-12225919-B2 | Taste-masking formulation for ketone body compounds | NEUROENERGY VENTURES, INC. (US) | 2025-02-18 | — | — | US | claimed |
| CN-113543652-B | Taste masking formulations for ketone body compounds | 神经活力投资公司 | 2024-07-05 | — | — | CN | claimed |
| CN-113329992-B | Process for the production of hydroxycarboxylic esters based on polyols | 凯托利皮克斯治疗有限责任公司 | 2024-04-30 | — | — | CN | claimed |
| CN-114008015-B | Process for the preparation of polyhydric alcohol esters of hydroxycarboxylic acids, in particular polyglycerol esters | 凯托利皮克斯治疗有限责任公司 | 2024-02-20 | — | — | CN | claimed |
| EP-3558458-B1 | GLYCERYL 3-HYDROXYBUTYRATES FOR MIGRAINE SYMPTOM MANAGEMENT | NEUROENERGY VENTURES INC (US) | 2023-10-18 | — | — | EP | claimed |
| CN-116209696-A | Process for preparing polyglycerol esters of 3-hydroxybutyric acid crosslinked with polycarboxylic acids | IOI油脂化学品有限责任公司 | 2023-06-02 | — | — | CN | claimed |
| US-11638702-B2 | Glyceryl 3-hydroxybutyrates for traumatic brain injury | NeuroEnerygy Ventures, Inc. (US) | 2023-05-02 | — | — | US | claimed |
| CN-110167637-B | Use of glycerol 3-hydroxybutyrate for migraine symptom management | 神经活力投资公司 | 2023-03-14 | — | — | CN | claimed |
| US-20220338510-A2 | Taste-Masking Formulation For Ketone Body Compounds | NEUROENERGY VENTURES, INC. (US) | 2022-10-27 | — | — | US | claimed |
| WO-2018132189-A1 | GLYCERYL 3-HYDROXYBUTYRATES FOR TRAUMATIC BRAIN INJURY | NEUROENERGY VENTURES, INC. (US) | 2018-07-19 | — | — | WO | claimed |
| US-20180193300-A1 | GLYCERYL 3-HYDROXYBUTYRATES FOR TRAUMATIC BRAIN INJURY | NEUROENERGY VENTURES, INC. (US) | 2018-07-12 | — | — | US | claimed |
| WO-2018118369-A1 | GLYCERYL 3-HYDROXYBUTYRATES FOR MIGRAINE SYMPTOM MANAGEMENT | NEUROENERGY VENTURES,INC. (US) | 2018-06-28 | — | — | WO | claimed |
| US-20180177753-A1 | GLYCERYL 3-HYDROXYBUTYRATES FOR MIGRAINE SYMPTOM MANAGEMENT | NEUROENERGY VENTURES, INC. (US) | 2018-06-28 | — | — | US | claimed |
| US-9925164-B1 | Glyceryl 3-hydroxybutyrates for traumatic brain injury | NEUROENERGY VENTURES, INC. (US) | 2018-03-27 | — | — | US | claimed |
| EP-1648952-B1 | NUTRITIONAL SUPPLEMENTS AND THERAPEUTIC COMPOSITIONS COMPRISING (R)-3-HYDROXYBUTYRATE DERIVATIVES | THE US GOV AS REPRESENTED BY THE DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2018-03-07 | — | — | EP | claimed |
| WO-1995009144-A1 | NUTRITIVE WATER SOLUBLE GLYCEROL ESTERS OF HYDROXY BUTYRIC ACID | EASTMAN CHEMICAL COMPANY (US) | 1995-04-06 | — | — | WO | claimed |
| US-4701443-A | PARENTAL ADMINISTERING | BAXTER TRAVENOL LABORATORIES, INC. (US) | 1987-10-20 | — | — | US | claimed |
| EP-0139677-A1 | NUTRIENT POLYESTERS | BAXTER TRAVENOL LABORATORIES, INC. (US) | 1985-05-08 | — | — | EP | claimed |
| WO-1984003626-A1 | NUTRIENT POLYESTERS | BAXTER TRAVENOL LAB (US) | 1984-09-27 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180177753-A1 | GLYCERYL 3-HYDROXYBUTYRATES FOR MIGRAINE SYMPTOM MANAGEMENT | HTR3B, MGLL, HTR3A | KDM4E 2988/4885DUSP3 3128/4885MEN1 1094/4885 |
| US-20180193300-A1 | GLYCERYL 3-HYDROXYBUTYRATES FOR TRAUMATIC BRAIN INJURY | FABP7, B3GAT3, PYGB | KDM4E 3535/4885DUSP3 4584/4885MEN1 3920/4885 |
| US-11638702-B2 | Glyceryl 3-hydroxybutyrates for traumatic brain injury | FABP7, B3GAT3, PYGB | KDM4E 3535/4885DUSP3 4584/4885MEN1 3920/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.